President's Budget Pushes Research

University-based researchers have reason for optimism following President Bill Clinton's request in his fiscal year (FY) 2001 budget for a $2.8 billion increase in science funding. As negotiations begin in Congress on the long, bumpy track toward budget approval, the fastest starter out of the gate is the National Science Foundation, which would receive double the largest dollar increase in its half-century of existence. The National Institutes of Health likewise is in line for a substantial fun

Written bySteve Bunk
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

University-based researchers have reason for optimism following President Bill Clinton's request in his fiscal year (FY) 2001 budget for a $2.8 billion increase in science funding. As negotiations begin in Congress on the long, bumpy track toward budget approval, the fastest starter out of the gate is the National Science Foundation, which would receive double the largest dollar increase in its half-century of existence. The National Institutes of Health likewise is in line for a substantial funding rise. The question is, how can spending caps be avoided to effect these increases?

In 1997, when Congress decided to balance the federal budget by FY2002, caps were set on discretionary spending, the portion of the federal budget out of which almost all federal R&D is funded. Although the budget went into surplus in FY1998, the caps remain in place. In FY1999, those limits were circumvented by the designation of $21 billion as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies